Seeking Alpha
12 Jun 2026, 07:46 UTC · 2h ago
Abbott Laboratories Remains Structurally Undervalued
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
12 Jun 2026, 07:46 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Abbott Laboratories has raised its FY26 guidance for both sales and earnings per share (EPS). — Upward revisions to future earnings guidance typically trigger immediate positive price action and investor confidence.
+0.60Abbott is currently trading at a 17.1% P/E and 35.1% sales multiple discount relative to its peers. — Significant structural undervaluation suggests a potential for a valuation rerating if fundamentals remain strong.
+0.40The company is pursuing growth through the acquisition of Exact Sciences and global expansion of its continuous glucose monitoring (CGM) business. — Strategic acquisitions and expansion into high-growth diagnostics markets provide long-term catalysts for revenue growth.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
Rated as a strong buy with structural undervaluation, fair value upside, and raised FY26 guidance.
Mentioned as a driver of growth for Abbott Laboratories via acquisition.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
38m ago
